|
Diabetes Medication Article
Why is Insulin prescribed?
Insulin is a hormone produced in the pancreas. Insulin is necessary to move sugar from the blood into other body tissues where it is needed for energy. Insulin also helps the body to metabolize (process) carbohydrates, fats, and proteins from the diet. In a person with diabetes, the pancreas does not produce enough insulin for the body's needs, so additional insulin is required. It must be injected because stomach acid would destroy it if taken by mouth. Insulin controls, but does not cure, diabetes. It must be taken regularly. People with diabetes gradually develop serious nerve, blood vessel, kidney, and eye problems, especially if the diabetes is not controlled properly.
This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Lantus Drug News
Lantus Drug
IMPORTANT: Bing News RSS feed has moved!
Details were not disclosed for most of the studies, as the majority have not yet completed, but GSK did announce findings from one trial testing albiglutide against Lilly's insulin drug Humalog given on top of Sanofi's Lantus. In that trial ...
Read moreGSK says new data support filing of diabetes drug
He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute (FRI), he led the successful in-licensing of the GK1-399 program and ...
Read moreNoah Rosenberg, MD, Joins Esperion Therapeutics as Chief Medical Officer
Both treatments were given on top of insulin glargine (Lantus). Patients taking the investigational agent saw an HbA1c reduction of 0.82% compared with a 0.66% reduction for those on preprandial lispro insulin (P<0.0001 for noninferiority).
Read moreWeekly Drug May Substitute for Pre-Meal Insulin
Several major biotech drugs such as Roche’s Herceptin and Rituxan, Sanofi’s Lantus, Amgen’s Neulasta are expected to lose patents, starting from the year 2012. This would translate into tremendous opportunities for biosimilar manufacturers in the coming years.
Read moreGlobal Biosimilars Market to Reach US$17.9 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.
The study that has done a robust analysis on 21 biopharmaceuticals facing biosimilar competition expects the combined sales of Amgens four drugs to decline by US$ ... Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon ...
Read more